Kaiser Permanente Division of Research, Oakland, California, USA.
Vitalant Research Institute, San Francisco, California, USA.
Transfusion. 2020 Nov;60(11):2548-2556. doi: 10.1111/trf.16059. Epub 2020 Sep 9.
Consensus definitions for transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) have recently been revised; however, pulmonary transfusion reactions remain difficult to diagnose. We hypothesized that N-terminal pro-brain natriuretic peptide (NT-proBNP) levels could have utility in the identification and classification of pulmonary transfusion reactions.
We performed a secondary analysis of a case-control study of pulmonary transfusion reactions at four academic hospitals. We evaluated clinical data and measured NT-proBNP levels prior to and following transfusion in patients with TACO (n = 160), transfused acute respiratory distress syndrome (ARDS) [n = 51], TRALI [n = 12], TACO/TRALI [n = 7], and controls [n = 335]. We used Wilcoxon Rank-Sum tests to compare NT-proBNP levels, and classification and regression tree (CART) algorithms to produce a ranking of covariates in order of relative importance for differentiating TACO from transfused controls.
Pre-transfusion NT-proBNP levels were elevated in cases of transfused ARDS and TACO (both P < .001) but not TRALI (P = .31) or TACO/TRALI (P = .23) compared to transfused controls. Pre-transfusion NT-proBNP levels were higher in cases of transfused ARDS or TRALI with a diagnosis of sepsis compared to those without (P < .05 for both). CART analyses resulted in similar differentiation of patients with TACO from transfused controls for models utilizing either NT-proBNP levels (AUC 0.83) or echocardiogram results (AUC 0.80).
NT-proBNP levels may have utility in the classification of pulmonary transfusion reactions. Prospective studies are needed to test the predictive utility of pre-transfusion NT-proBNP in conjunction with other clinical factors in identifying patients at risk of pulmonary transfusion reactions.
最近修订了与输血相关的急性肺损伤(TRALI)和输血相关循环超负荷(TACO)的共识定义;然而,肺部输血反应仍然难以诊断。我们假设 N 端脑利钠肽前体(NT-proBNP)水平可用于识别和分类肺部输血反应。
我们对四家学术医院的肺部输血反应病例对照研究进行了二次分析。我们评估了 TACO(n=160)、输血性急性呼吸窘迫综合征(ARDS)[n=51]、TRALI[n=12]、TACO/TRALI[n=7]和对照组[n=335]患者输血前后的临床数据和 NT-proBNP 水平。我们使用 Wilcoxon 秩和检验比较 NT-proBNP 水平,并使用分类和回归树(CART)算法根据区分 TACO 与输血对照的相对重要性对协变量进行排序。
与输血对照相比,输血性 ARDS 和 TACO(均 P<0.001)但不是 TRALI(P=0.31)或 TACO/TRALI(P=0.23)患者的输血前 NT-proBNP 水平升高。与无败血症诊断的输血性 ARDS 或 TRALI 患者相比,有败血症诊断的输血性 ARDS 或 TRALI 患者的输血前 NT-proBNP 水平更高(均 P<0.05)。CART 分析导致使用 NT-proBNP 水平(AUC 0.83)或超声心动图结果(AUC 0.80)的模型对 TACO 患者与输血对照的区分相似。
NT-proBNP 水平可能有助于肺部输血反应的分类。需要前瞻性研究来测试输血前 NT-proBNP 与其他临床因素联合识别肺部输血反应风险患者的预测效用。